Memery Crystal starts 2024 advising on three fundraisings

Valirx plc., the AIM listed life science company focusing on cancer therapeutics and women’s health, raised approximately £1.8 million before expenses pursuant to its fundraising round. Valirx intends to apply the proceeds towards R&D, commercial development and brand establishment.

Kelso Group Holdings plc, the Main Market-listed acquisition vehicle, raised £1.88 million before expenses. Kelso intends to use the proceeds to continue to execute its mandate to engage and unlock trapped value in the UK stock market.

Graft Polymer plc, the Main Market-listed, multi-sector specialist chemical company offering modified and alloyed polymer and bio-polymer solutions, raised funds from a cornerstone investor and its own board.

The Memery Crystal team was led by Senior Partner Nick Davis and Partner Robert-Bines Black, who were assisted by Senior Associate Amanpreet Deusi.

Nick Davis commented: “It is encouraging to see our Corporate team off to a great start this year, with three fundraisings completing in short succession. Our Equity Capital Markets team was strengthened in 2023 with two new Partner hires and we continue to provide an efficient, thorough and commercial service to our company and broker clients.”